A number of clinical trials have studied the potential role of romosozumab, a humanized anti-sclerostin mAb, in osteoporosis but no studies have been initiated in MM patients and are not likely to in view of a recent report of serious cardiovascular events found in a significant proportion of patients receiving romosozumab in a phase III comparison with alendronate in osteoporosis. The gene discussed is SOST; the disease is Miyoshi myopathy.